The research report was punished by the "rollover", and the Shanghai Securities Police Letter Letter, the deputy director and analyst of the research institute were supervised and talked about

Earlier this year, Shanghai Securities released a research report on Anxu Bio (SH688075, a stock price of 18.2.83 yuan, and a market value of 11.214 billion), entitled "Autonomous and Controlling the Raw Materials, Leading POCT Testing and Development", which attracted Anx Bio to clarify the explanation. Essence

After a lapse of half a year, on June 17, the Shanghai Securities Regulatory Bureau announced that the research report released by Shanghai Securities has insufficient reasonable basis for the reasonable basis of analysis conclusions, and the quality control before the research report was released. Therefore, Shao Rui, deputy director of Shanghai Securities and Shanghai Securities Research Institute, and Huang Zhuo, a signed analyst, have taken corresponding regulatory measures.

Shanghai Securities and the two were punished for a research report

On June 17, the Shanghai Securities Regulatory Bureau issued a decision to take a warning measures for Shanghai Securities. The Shanghai Securities Regulatory Bureau believes that the reasonable basis of the securities research report issued by Shanghai Securities has insufficient analysis conclusions, and the quality control before the research report was released.

In addition to the supervision and management measures for Shanghai Securities with alert letter, it is also required that Shanghai Securities should be regarded as a warning, carefully searching and rectification issues, continuously improving internal control, and submitting a written rectification report within 30 days from the date of receipt of the decision.

In addition, the reporter of "Daily Economic News" also noticed that the Shanghai Securities Regulatory Bureau also took regulatory conversation measures on the two personnel. The Shanghai Securities Regulatory Bureau stated that Shao Rui, as the deputy director of the Shanghai Securities Research Institute, is responsible for the lack of quality control before the company's research report was released; The reasonable basis is not fully responsible.

The annual report of Shanghai Securities 2021 pointed out that the company's research institute actively transformed seller research services to build the seller's research team and sales team, and completed the four total teams including macro, solidarity, strategy, and gold workers. Electronics, media, real estate and building materials, social uniforms and other specialized research teams have set up a research professional sales team covering Shanghai, Beijing, and Guangshen. Sales service power. According to data from the Securities Industry Association, the number of analysts in Shanghai securities is 32.

Earlier this year's research report on Anxu's biology "rollover"

Earlier this year, the concept of new crown testing became one of the hottest sections of the A -shares in 2022, and Anxu's biological stock price also rose sharply. On January 11, Shanghai Securities issued a research report "Anxu Biology: Autonomous and Controlling Raw Materials, Leading POCT Testing and Development", and the investment recommendations are recommended to "buy" rating.

Picture source: screenshot of Shanghai Securities Research Report

The report states that it is estimated that the Biology Bio will achieve a net profit of 726 million yuan/2.988 billion yuan/1.655 billion yuan from 2021 ~ 2023, an increase of 11.9%/311.5%/-44.6%year-on-year, and the corresponding EPS is 11.84 yuan/48.72 yuan. /26.98 yuan, PE valuation from 2021 to 2023 was 15.08 times /3.67 times /6.62 times. Continue to be optimistic about the wide market POCT detection track. At the same time, the company belongs to the high -quality track with high self -supply capacity, a core POCT reagent provider with rich categories, and is expected to be significantly thickened by the overseas epidemic catalytic catalysis and exclusive self -test pen sales. Product research and development, channel expansion and production capacity improvement, broad prospects.

However, on the night of January 11, An Xu Biological issued a clarification announcement stating that the company paid attention to the profit forecast of the performance from 2022 to 2023, but the company has not accepted Shanghai Securities relevant personnel personnel personnel personnel personnel have not accepted Shanghai Securities relevant personnel. Any form of interview survey and other activities have never provided the relevant performance data and business data that have not been disclosed to the outside world. The report is the opinion of Shanghai Securities Research Institute and does not represent the company's position.

Picture source: Anxu Biological Announcement Screenshot

In addition, An Xu Bio also emphasized at that time that the company's new coronary virus antigen self -test products and new coronary virus antigen nasal detection reagents (self -test) have recently obtained EU CE certification, which is relatively late. The above -mentioned product certification is not exclusive to the company. There are similar products or other test products in the market. The company's products will still face fierce market competition risks.

At the beginning of the year, the Research Report of Junior CITI Securities was also clarified by listed companies

In fact, the "rollover" of the brokerage company's research report caused the listed company to clarify occasionally occasionally. Earlier this year, in addition to the aforementioned Shanghai Securities, the research report released by CITIC Securities (SH600030, stock price of 20.82 yuan, and a market value of 308.6 billion) was "faced" by listed companies.

On January 13 this year, CITIC Securities issued a major comments on Oriental Oriental (SH688298, a stock price of 132.80 yuan, and a market value of 22.3 billion), namely "The United States launched a new crown fast detection plan, breeding the new blue ocean of antigen detection, and raising target price" Research report. The report states that, given the company's new US antigen testing market, considering the population base and the number of confirmed cases in recent days, it is expected that the overall US antigen test market demand space is more than twice the European market, and the supply pattern is better, and the blue sea market characteristics are significant.

Picture source: Screenshot of CITIC Securities Research Report

The above research report has further stated that the company and Siemens's in -depth cooperation model have been verified in the European market. It is expected that the continuous profitability in the US market will exceed market expectations.Relding 2021 ~ 2023 EPS prediction to 45.04 yuan/75.49 yuan/40.25 yuan (the original prediction was 41.67 yuan/19.28 yuan/19.96 yuan), and the target price was raised to 528 yuan (Note: The stock price of Oriental biological biological stocks was 350.02 yuan at the time of the report.Rehabilitation of 241.82 yuan), corresponding to 7 times PE in 2022, maintains the "buy" rating.

Regarding the content in CITIC Securities Research Report, Oriental Bio announced on January 14th that the stock transaction abnormal fluctuation announcement stated that the company paid attention to the company's sales of the company's performance from 2022 to 2023.The opinion of the CITIC Securities Research Department does not represent the company's position; the company has not provided the relevant business performance data that has not been disclosed to the outside world; it has not done any operating performance forecast from 2022 to 2023.

Image source: Screenshot of Oriental Biological Announcement

Daily Economic News

- END -